Vol. 4 No. 4 (2024)
Reimbursement Recommendations

Nirmatrelvir-Ritonavir (Paxlovid)

decorative image of the issue cover

Published April 30, 2024

Key Messages

  • CADTH recommends that Paxlovid be reimbursed by public drug plans for the treatment of mild to moderate COVID-19 in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death, if certain conditions are met.
  • Paxlovid should only be covered to treat patients who have severe or moderate immunosuppression as described in Table 1. Treatment should be initiated as soon as possible within 5 days of symptom onset.
  • Paxlovid should only be reimbursed if the cost is reduced.